Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2007 Dec;4(12):e346.
doi: 10.1371/journal.pmed.0040346.

Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing

Matthias Götte  1
Affiliations
Comment

Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing

Matthias Götte. PLoS Med. 2007 Dec.

Abstract

The author discusses a new study that found a common mutation in the connection domain of reverse transcriptase, a mutation that confers resistance to two antiretroviral drug classes.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The author has declared that no competing interests exist.

Comment on

References

    1. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003;37:113–128. - PubMed
    1. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA) AIDS. 2002;16:369–379. - PubMed
    1. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 2000;14:F83–F93. - PubMed
    1. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 2002;16:209–218. - PubMed
    1. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999;353:2195–2199. - PubMed

MeSH terms

Substances